首页> 外文学位 >Regulation of P-glycoprotein by Nuclear Receptors at the Blood-Brain Barrier: Relevance to Human Immunodeficiency Virus - 1 Pharmacotherapy.
【24h】

Regulation of P-glycoprotein by Nuclear Receptors at the Blood-Brain Barrier: Relevance to Human Immunodeficiency Virus - 1 Pharmacotherapy.

机译:血脑屏障中核受体对P糖蛋白的调节:与人类免疫缺陷病毒的相关性-1药物治疗。

获取原文
获取原文并翻译 | 示例

摘要

ATP-binding cassette membrane-associated drug efflux transporters expressed at the blood-brain barrier (BBB) are important determinants of drug disposition in the central nervous system. Targeting the regulatory pathways that govern the expression of drug transporters, such as P-glycoprotein (P-gp) could provide novel approaches to selectively alter drug permeability in the brain. Pregnane X Receptor (PXR) and Constitutive Androstane Receptor (CAR) are ligand-activated nuclear receptors which regulate the gene expression of several drug transporters, including P-gp. Currently, knowledge on their significance at the BBB is limited. The overall goal of this Ph.D. thesis was to examine the role of these two nuclear receptors in the regulation of P-gp functional expression in brain microvessel endothelial cells, an important compartment constituting the BBB, and in a mouse model. We demonstrated hPXR and hCAR protein expression in two human brain microvessel endothelial cell culture models (i.e., hCMEC/D3 and primary cultures of human brain-derived microvascular endothelial cells). We further showed the in vitro role of hPXR and hCAR in regulating P-gp functional expression in the hCMEC/D3 cells. In addition, results obtained from Luciferase reporter gene assays demonstrated that several antiretroviral drugs currently used in the clinic are ligands for hPXR (i.e., amprenavir, atazanavir, darunavir, efavirenz, ritonavir and lopinavir) and hCAR (i.e., abacavir, efavirenz and nevirapine). These drugs significantly induced P-gp functional expression in hCMEC/D3 cells at clinical plasma concentrations. Applying quantitative intracerebral microdialysis in CD-1 mice, we observed that P-gp induction mediated by a mouse PXR ligand/P-gp inducer (i.e., dexamethasone) at the BBB significantly decreased the ratios of quinidine (an established P-gp substrate) concentrations in brain extracellular fluid to unbound plasma concentrations at steady state (Kp,uu,ECF/Plasma) when compared to vehicle-treated animals. Taken together, our data provide evidence that hPXR and hCAR could be potential xenobiotic targets for the regulation of P-gp at the BBB. This work will guide future development of novel pharmacotherapy that could target these receptors to alter drug transporters functional expression at the BBB, resulting in either enhanced CNS drug efficacy or reduced drug-associated neurotoxicity.
机译:在血脑屏障(BBB)中表达的ATP结合盒膜相关药物外排转运蛋白是中枢神经系统中药物处置的重要决定因素。靶向控制药物转运蛋白(例如P-糖蛋白(P-gp))表达的调节途径可以提供选择性改变大脑中药物渗透性的新颖方法。孕烷X受体(PXR)和组成型雄激素受体(CAR)是配体激活的核受体,可调节多种药物转运蛋白(包括P-gp)的基因表达。目前,关于其在血脑屏障中的重要性的知识有限。该博士的总体目标本论文旨在研究这两种核受体在调节脑微血管内皮细胞(构成血脑屏障的重要部位)的P-gp功能表达中的作用,以及在小鼠模型中的作用。我们在两种人脑微血管内皮细胞培养模型(即hCMEC / D3和人脑衍生的微血管内皮细胞的原代培养)中证明了hPXR和hCAR蛋白的表达。我们进一步显示了hPXR和hCAR在调节hCMEC / D3细胞中P-gp功能表达中的体外作用。此外,从萤光素酶报告基因检测获得的结果表明,目前临床上使用的几种抗逆转录病毒药物是hPXR(即安普那韦,阿扎那韦,达鲁那韦,依非韦伦,利托那韦和洛匹那韦)和hCAR(即阿巴卡韦,依非韦伦和奈韦拉平)的配体。这些药物在临床血浆浓度下可显着诱导hCMEC / D3细胞中P-gp功能性表达。在CD-1小鼠中应用定量脑微透析,我们观察到在BBB处由小鼠PXR配体/ P-gp诱导剂(即地塞米松)介导的P-gp诱导显着降低了奎尼丁(已建立的P-gp底物)的比率。与媒介物处理的动物相比,脑细胞外液中的血药浓度达到稳态时未结合的血浆浓度(Kp,uu,ECF /血浆)。综上所述,我们的数据提供了证据,证明hPXR和hCAR可能是BBB调节P-gp的潜在异种靶标。这项工作将指导新型药物疗法的未来发展,该药物疗法可以靶向这些受体以改变BBB处的药物转运蛋白功能表达,从而导致中枢神经系统药物疗效增强或药物相关神经毒性降低。

著录项

  • 作者

    Chan, Gary Ngai Yin.;

  • 作者单位

    University of Toronto (Canada).;

  • 授予单位 University of Toronto (Canada).;
  • 学科 Pharmacology.
  • 学位 Ph.D.
  • 年度 2013
  • 页码 369 p.
  • 总页数 369
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号